Based on the success of the 2018 Theranostics Consensus Conference and the 2019 categorial Theranostics: Regulatory Considerations for Product Development—co-hosted by SNMMI, FDA, and the National Cancer Institute (NCI)—major stakeholders in theranostics, including the FDA, NCI, academicians, clinical physicians, and pharmaceutical company executives will once again gather at the National Cancer Institute – Shady Grove, Maryland, for a day of in-depth discussions.
The conference will focus on maximizing dose to tumor while sparing normal tissue, the current state of the science, state of the art clinical trial design, and strategies for achieving response.
Note: This event is invitation only. Contact us for more information.
A discounted hotel room block is available for registered attendees at the Hilton Garden Inn Rockville-Gaithersburg. Click here to make your hotel reservation.
Download a copy of the agenda.
Theme: What is the goal with radionuclide therapies - palliative, curative, or adjuvant treatment? |
|
8:00–8:15 am |
Opening Remarks |
Session One: Maximizing dose to tumor while sparing normal tissue |
|
8:15–8:35 am |
High vs. low LET radionuclides |
8:35–8:55 am |
Using imaging to assess the dose effect on tumor and normal tissue |
8:55–9:25 am |
Panel discussion: Modeling and Measuring Dose Effects |
Session Two: Current State of the Science: Maximizing treatment efficacy |
|
9:25–9:50 am |
Normal tissue toxicity – normal tissue limits from low-dose rate radiation effects |
9:50–10:10 am |
Agent Optimization: ADME, Dose and Decay |
10:10–10:30 am |
Landscape Analysis: Summary of Phase 1 Agents |
10:30-10:50 am |
Break |
10:50–11:20 am |
Panel discussion: Targeting strategies for radionuclide delivery |
Session Three: Current State of the Art: Clinical Trials Design |
|
11:20–11:40 am |
Safety Considerations and Use of Quantitative Imaging |
11:40 am–12:00 pm |
Landscape Analysis: Summary of Phase 2 and 3 Agents |
12:00–1:00 pm |
Lunch |
1:00–1:20 pm |
Clinical Trial Design Strategies: The Australian Experience |
1:20–1:40 pm |
Clinical Trial Design Strategies: The German Experience |
1:40–1:50 pm |
Clinical Trial Design: FDA Perspective |
1:50–2:20 pm |
Panel discussion: Assessing human toxicities – short and long-term |
Session Four: Achieving Response: Strategies |
|
2:20–2:40 pm |
Where is the gap? Framing the right question(s) |
2:40–3:00 pm |
Prioritization of trial objectives: Analysis of treatment failures and conditions that led to Failure |
3:00–3:20 pm |
FDA Perspective: Therapeutic clinical development considerations FDA Perspective: Diagnostic clinical development considerations |
3:20–3:40 pm |
Industry’s perspective |
3:40-4:00 pm |
Break |
4:00–4:30 pm |
Panel discussion: Rationale for combination therapies, sensitization. and normal tissue protection |
4:30–5:00 pm |
Publication Planning and Meeting Summary |
SNMMI would like to thank the following organizations for sponsoring this event.
Limited sponsorship opportunities are still available. Contact us for details.
Title Sponsor | ||